RaQualia Pharma Inc. (TYO:4579)

RaQualia Pharma Balance Sheet

Financials in millions JPY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	4,575	3,240	3,340	3,714	3,675	2,345
Short-Term Investments	121	3	1	49	250	313
Cash & Short-Term Investments	4,696	3,243	3,341	3,763	3,925	2,658
Cash Growth	29.65%	-2.93%	-11.21%	-4.13%	47.67%	25.79%
Receivables	852	1,928	689	603	602	1,205
Inventory	164	159	167	147	8	10
Prepaid Expenses	345	165	193	188	108	90
Other Current Assets	133	187	148	255	179	40
Total Current Assets	6,190	5,682	4,538	4,956	4,822	4,003
Property, Plant & Equipment	449	436	529	573	391	299
Long-Term Investments	717	598	607	1,306	1,020	897
Goodwill	3,560	3,700	3,865	-	-	-
Other Intangible Assets	27	32	37	30	24	33
Long-Term Deferred Tax Assets	62	64	78	5	-	-
Other Long-Term Assets	1	2	1	1	-	2
Total Assets	11,006	10,514	9,655	6,871	6,257	5,234

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	68	73	59	54	128	45
Accrued Expenses	60	58	69	54	60	63
Current Portion of Long-Term Debt	512	512	512	12	2	-
Current Portion of Leases	95	78	69	64	42	21
Current Income Taxes Payable	199	320	221	178	237	230
Other Current Liabilities	137	234	257	27	24	41
Total Current Liabilities	1,071	1,275	1,187	389	493	400
Long-Term Debt	1,882	2,138	2,651	39	9	-
Long-Term Leases	195	171	218	251	167	17
Long-Term Deferred Tax Liabilities	-	-	-	-	2	16
Other Long-Term Liabilities	27	35	28	73	89	15
Total Liabilities	3,175	3,619	4,084	752	760	448

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	3,952	3,240	2,720	2,667	2,265	2,256
Additional Paid-In Capital	4,142	3,430	2,910	2,857	2,455	2,446
Retained Earnings	-239	227	-45	449	773	49
Comprehensive Income & Other	-24	-2	-14	146	4	35
Shareholders' Equity	7,831	6,895	5,571	6,119	5,497	4,786
Total Liabilities & Equity	11,006	10,514	9,655	6,871	6,257	5,234

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	2,684	2,899	3,450	366	220	38
Net Cash (Debt)	2,012	344	-109	3,397	3,705	2,620
Net Cash Growth	371.19%	-	-	-8.31%	41.41%	26.69%
Net Cash Per Share	78.93	14.30	-5.04	157.22	176.57	124.93
Filing Date Shares Outstanding	26.03	26.02	21.84	21.62	21.6	20.96
Total Common Shares Outstanding	26.03	24.46	21.84	21.62	20.98	20.95
Working Capital	5,119	4,407	3,351	4,567	4,329	3,603
Book Value Per Share	300.83	281.91	255.10	282.98	262.05	228.43
Tangible Book Value	4,244	3,163	1,669	6,089	5,473	4,753
Tangible Book Value Per Share	163.03	129.32	76.43	281.60	260.90	226.86

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 25, 2026

Data Sources Report a data error